Viewing nowCombinationHarbika Tablet 10/40 Milligrams
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
White Life Sciences Co., Ltd.

MFDS item code 201404728 · Approved 2014.10.15 · Insurance code 625200910
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively control blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with Amlodipine or Olmesartan Medoxomil. It helps reduce the risk of cardiovascular complications associated with hypertension and maintains healthy blood pressure levels.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time every day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using amlodipine 5 mg or olmesartan medoxomil 20 mg. - 10/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using olmesartan medoxomil 20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not be administered this medicine under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Under 18 years of age: The safety and efficacy of this medicine have not been established in pediatric patients.
This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, therefore it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in individuals allergic to the active ingredients or similar components, pregnant or nursing women, patients with severe liver impairment, severe aortic stenosis, biliary obstruction, patients on kidney dialysis, patients in shock, certain diabetic patients, and patients with moderate or worse kidney impairment. In patients with hypotension due to fluid or salt depletion, hypotensive symptoms may occur, therefore, careful monitoring of the condition is required upon initial intake, and appropriate measures should be taken if hypotension develops. Patients with heart-related conditions such as aortic stenosis, obstructive coronary artery disease, and congestive heart failure should use caution as rapid vasodilation may lead to hypotension. For patients with reduced kidney function, kidney function may worsen, thus regular monitoring is needed, and patients with impaired liver function should also be monitored closely. Common side effects during treatment include dizziness, headache, low blood pressure, swelling, dyspepsia, and skin rash; however, severe side effects have also been reported, so immediate consultation with healthcare professionals is necessary upon the onset of unusual symptoms. This medication may interact with certain drugs, so inform your doctor or pharmacist if you are taking other medications, particularly avoiding co-administration with grapefruit juice. Use of this medication should be avoided during pregnancy and alternative safe treatments should be sought if pregnancy is planned or confirmed. There is a possibility that this medication may be excreted in breast milk and cause side effects in infants, so it is recommended to either discontinue breastfeeding or stop taking the medication. Use in pediatric patients under 18 years is not recommended as safety and efficacy have not been established. For elderly patients, it is advisable to start with a low dose considering potential decline in kidney and liver function, and to monitor for adverse reactions during treatment. In cases of overdose, hypotension and tachycardia may occur, so if overdose is suspected, immediate treatment in a medical institution should be sought. This medication should be stored out of reach of children and protected from moisture, heat, and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. Additionally, the medication should be stored at room temperature, ideally between 1 and 30 degrees Celsius.
Reddish-brown round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
White Life Sciences Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.